Seamus Fernandez
Stock Analyst at Guggenheim
(4.85)
# 79
Out of 5,113 analysts
116
Total ratings
68.67%
Success rate
42.15%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,161 | $1,039.51 | +11.69% | 23 | Jan 20, 2026 | |
| GPCR Structure Therapeutics | Maintains: Buy | $90 → $140 | $89.51 | +56.41% | 3 | Jan 20, 2026 | |
| MBX MBX Biosciences | Maintains: Buy | $77 → $88 | $36.07 | +143.97% | 5 | Jan 16, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $14 → $25 | $14.75 | +69.49% | 3 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $120 → $140 | $105.53 | +32.66% | 3 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $62 | $55.56 | +11.59% | 13 | Dec 12, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $47.49 | - | 1 | Dec 9, 2025 | |
| IVA Inventiva | Maintains: Buy | $13 → $11 | $6.87 | +60.12% | 1 | Nov 18, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $7.46 | - | 4 | Oct 23, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $15.47 | +61.60% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $72.38 | +60.27% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $26.33 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $54.35 | +194.39% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $32.84 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $107.92 | +13.05% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $50.80 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.18 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $62.89 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $152.22 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.72 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.87 | +1,295.35% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $26.23 | +71.56% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $95.60 | -60.25% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.50 | +43.40% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Jan 20, 2026
Maintains: Buy
Price Target: $1,163 → $1,161
Current: $1,039.51
Upside: +11.69%
Structure Therapeutics
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $89.51
Upside: +56.41%
MBX Biosciences
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $36.07
Upside: +143.97%
Tenax Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $14 → $25
Current: $14.75
Upside: +69.49%
Rhythm Pharmaceuticals
Dec 17, 2025
Maintains: Buy
Price Target: $120 → $140
Current: $105.53
Upside: +32.66%
Bristol-Myers Squibb Company
Dec 12, 2025
Upgrades: Buy
Price Target: $62
Current: $55.56
Upside: +11.59%
Sanofi
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $47.49
Upside: -
Inventiva
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $6.87
Upside: +60.12%
Arcturus Therapeutics Holdings
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $7.46
Upside: -
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $15.47
Upside: +61.60%
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $72.38
Upside: +60.27%
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $26.33
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $54.35
Upside: +194.39%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $32.84
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $107.92
Upside: +13.05%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $50.80
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.18
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $62.89
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $152.22
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.72
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.87
Upside: +1,295.35%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $26.23
Upside: +71.56%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $95.60
Upside: -60.25%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.50
Upside: +43.40%